GRI Bio announces the granting of two global patents for Europe, Japan

GRI Bio (GRI) announced the granting of two global patents. The granted patents include: Europe patent application No. 19,166,502 titled, “Oxygenated Amino- or Ammonium-Containing Sulfonic Acid, Phosphonic Acid and Carboxylic Acid Derivatives and Their Medical Use.” The patent claims include coverage of GRI-0803, the Company’s novel activator of human type 2 diverse NKT cells in development for the treatment of autoimmune disorders, with an initial focus on systemic lupus erythematosus. Activation of dNKT leads to a dendritic cell-mediated inhibition of type 1 invariant NKT cells. Japan application No. 2023-000750 titled, “Prevention and Treatment of Inflammatory Conditions.” This patent covers claims including compositions and methods for modulating dNKT and/or iNKT cells in the prevention and treatment of inflammatory conditions. More specifically, the patent covers the prevention and treatment of inflammatory, fibrotic and autoimmune conditions through the administration of a Retinoic Acid Receptor agonist that inhibits iNKT cells in a subject.